Cutaneous T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-28Clinical Trial Update: VircapSeq Virus Detection in Sézary Syndrome
A completed study evaluated VircapSeq virus detection in patients with Sézary syndrome, a form of cutaneous T-cell lymphoma, with results po…
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides [NA]
This trial evaluated biodynamic imaging to predict response to gemcitabine in cutaneous T-cell lymphoma (mycosis fungoides); the study was t…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Mogamulizumab Q4week Dosing in Participants With R/R CTCL [Phase 2]
Phase 2 trial update describes mogamulizumab dose every 4 weeks in relapsed/refractory cutaneous T-cell lymphoma participants; trial status …
-
CLINICAL_TRIALS trial_result · 2023-10-06Clinical Trial Update: L19IL2/L19TNF in Skin Cancer Patients [Phase 2]
Phase 2 clinical trial update for L19IL2/L19TNF in skin cancer patients with various skin cancers; status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study [Phase 1, Phase 2]
Phase 1/2 trial exploring linperlisib plus chidamide in relapsed/refractory cutaneous T-cell lymphoma; current status not provided.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: AFM13 in Relapsed/Refractory Cutaneous Lymphomas [Phase 1, Phase 2]
Phase 1/2 trial updates for AFM13 in relapsed/refractory cutaneous T-cell lymphoma have been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 trial update reporting pharmacokinetics and ECG determinations after 8 weeks of HyBryte treatment in Cutaneous T-Cell Lymphoma/Mycos…
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. [Phase 2]
Phase 2 trial update for HuMax-CD4 in cutaneous T-cell lymphoma (skin).
-
CLINICAL_TRIALS trial_result · 2023-05-11Clinical Trial Update: Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for non-myeloablative allogeneic transplantation using TLI and ATG in patients with cutaneous T-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. [Phase 2]
Phase 2 clinical trial update for HuMax-CD4 in advanced cutaneous T-cell lymphoma (skin).
-
CLINICAL_TRIALS trial_result · 2023-03-31Clinical Trial Update: Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) [Phase 2]
A Phase 2 clinical trial of dimethylfumarate (DMF) in patients with cutaneous T cell lymphoma has been completed.
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease [Phase 1, Phase 2]
Clinical trial update on modification of extracorporeal photopheresis for Cutaneous T-cell Lymphoma and chronic graft-versus-host disease in…
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers [Phase 1, Phase 2]
Phase 1/2 trial evaluating tremelimumab and IV durvalumab with Poly-ICLC in biopsy-accessible cancers; completed with results posted in 2022…
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms [Phase 2]
Phase 2 study of BGB-A317 (tislelizumab) in adults with relapsed or refractory mature T- and NK-cell neoplasms has completed, with results p…
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) [Phase 1]
Phase 1 trial evaluating subcutaneous recombinant human IL-15 in combination with alemtuzumab for refractory or relapsed adult T-cell leukem…
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) [Phase 3]
A Phase 3 trial of SGX301 (synthetic hypericin) topical treatment for cutaneous T-cell lymphoma (mycosis fungoides) has completed with poste…
-
CLINICAL_TRIALS trial_result · 2022-04-08Clinical Trial Update: SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides [Phase 2]
Phase 2 trial evaluating Cobomarsen (MRG-106) versus an active comparator in Mycosis Fungoides, a form of Cutaneous T-Cell Lymphoma; study t…
-
CLINICAL_TRIALS trial_result · 2022-01-25Clinical Trial Update: TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides [Phase 3]
A Phase 3 trial evaluating total skin electron beam therapy (low-dose) for eradicating tumor clones in early-stage mycosis fungoides (cutane…
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Mechlorethamine Induced Contact Dermatitis Avoidance Study [Phase 2]
Phase 2 clinical trial assessing avoidance of mechlorethamine–induced contact dermatitis in patients with cutaneous T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 trial of oral LBH589 (panobinostat) in adults with refractory cutaneous T-cell lymphoma completed; results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 clinical trial update for E7777 in relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma has completed rec…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]
Phase 2 study of oral LBH589 in adults with refractory/resistant cutaneous T-cell lymphoma (CTCL) was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL [Phase 1, Phase 2]
A dose-ranging study of IV BNZ-1 in LGL Leukemia or refractory cutaneous T-cell lymphoma (CTCL) has completed Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]
Phase 2 trial update for CD11301 in Cutaneous T-Cell Lymphoma (CTCL) assessing safety, efficacy, and pharmacokinetics.
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 [Phase 2]
Phase 2 extension study of mogamulizumab (KW-0761) for Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma in patients who relapsed aft…